Literature DB >> 25416658

Ambulatory blood pressure and adherence monitoring: diagnosing pseudoresistant hypertension.

Michel Burnier1, Gregoire Wuerzner2.   

Abstract

A small proportion of the treated hypertensive population consistently has a blood pressure greater than 140/90 mm Hg despite a triple therapy including a diuretic, a calcium channel blocker, and a blocker of the renin-angiotensin system. According to guidelines, these patients have so-called resistant hypertension. The prevalence of this clinical condition is higher in tertiary than primary care centers and often is associated with chronic kidney disease, diabetes, obesity, and sleep apnea syndrome. Exclusion of pseudoresistant hypertension using ambulatory or home blood pressure monitoring is a crucial step in the investigation of patients with resistant hypertension. Thus, among the multiple factors to consider when investigating patients with resistant hypertension, ambulatory blood pressure monitoring should be performed very early. Among other factors to consider, physicians should investigate patient adherence to therapy, assess the adequacy of treatment, exclude interfering factors, and, finally, look for secondary forms of hypertension. Poor adherence to therapy accounts for 30% to 50% of cases of resistance to therapy depending on the methodology used to diagnose adherence problems. This review discusses the clinical factors implicated in the pathogenesis of resistant hypertension with a particular emphasis on pseudoresistance, drug adherence, and the use of ambulatory blood pressure monitoring for the diagnosis and management of resistant hypertension.

Entities:  

Keywords:  Hypertension therapy; drug adherence; pseudohypertension; renal denervation; secondary hypertension

Mesh:

Substances:

Year:  2014        PMID: 25416658     DOI: 10.1016/j.semnephrol.2014.08.003

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  5 in total

1.  Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.

Authors:  Parisa Danaietash; Pierre Verweij; Ji-Guang Wang; George Dresser; Ilkka Kantola; Mary Katherine Lawrence; Krzysztof Narkiewicz; Markus Schlaich; Marc Bellet
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-06-09       Impact factor: 2.885

2.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 3.  Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension.

Authors:  Jordana B Cohen; Debbie L Cohen
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

Review 4.  A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider.

Authors:  Seyed Mehrdad Hamrahian; Omar H Maarouf; Tibor Fülöp
Journal:  Patient Prefer Adherence       Date:  2022-10-07       Impact factor: 2.314

5.  Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension.

Authors:  Zhiming Li; Jingguang Liu; Yuansheng Shen; Fanfang Zeng; Dongdan Zheng
Journal:  Lipids Health Dis       Date:  2016-01-22       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.